Mark Avagliano
2022
In 2022, Mark Avagliano earned a total compensation of $1.1M as Chief Business Officer at G1 Therapeutics, a 25% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $154,382 |
|---|---|
| Option Awards | $380,207 |
| Salary | $465,005 |
| Stock Awards | $128,280 |
| Other | $9,150 |
| Total | $1,137,024 |
Avagliano received $465K in salary, accounting for 41% of the total pay in 2022.
Avagliano also received $154.4K in non-equity incentive plan, $380.2K in option awards, $128.3K in stock awards and $9.2K in other compensation.
Rankings
In 2022, Mark Avagliano's compensation ranked 2,751st out of 5,542 executives tracked by ExecPay. In other words, Avagliano earned more than 50.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,751 out of 5,542 | 50th |
Division Manufacturing | 1,524 out of 3,000 | 49th |
Major group Chemicals And Allied Products | 703 out of 1,350 | 48th |
Industry group Drugs | 655 out of 1,253 | 48th |
Industry Pharmaceutical Preparations | 471 out of 907 | 48th |
Pay ratio
| Mark Avagliano's Pay | $1,137,024 |
|---|---|
| Median Employee's Pay | $243,930 |
| Pay Ratio | 5to 1 |
In 2022, the annual total compensation of Mark Avagliano was $1,137,024.
The annual total compensation of the median employee at G1 Therapeutics was $243,930.
The ratio of Mark Avagliano's pay to the pay of median employee was therefore 5 to one.
Source: SEC filing on April 26, 2023.
Avagliano's colleagues
We found two more compensation records of executives who worked with Mark Avagliano at G1 Therapeutics in 2022.